NR1H4 and metabolic dysfunction-associated steatohepatitis: Obeticholic acid (OCA), a clinically advanced therapeutic and farnesoid X receptor (FXR) agonist evaluated in phase III trials for the treatment of NASH [40], was used as an inhibitor control of lipid accumulation (Figure 1A).